Compare VYGR & AMRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | AMRO |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.5M | 166.1M |
| IPO Year | 2015 | 2026 |
| Metric | VYGR | AMRO |
|---|---|---|
| Price | $1.62 | $5.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | ★ $14.22 | $13.18 |
| AVG Volume (30 Days) | ★ 945.7K | 156.2K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,135,000.00 | N/A |
| Revenue This Year | N/A | $520.53 |
| Revenue Next Year | $172.11 | $49.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.48 | $3.99 |
| 52 Week High | $5.19 | $8.64 |
| Indicator | VYGR | AMRO |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 56.17 |
| Support Level | N/A | $5.26 |
| Resistance Level | $2.04 | $6.59 |
| Average True Range (ATR) | 0.15 | 0.62 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 16.22 | 49.68 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Amaero Inc specializes in manufacturing high-performance powders and near-net-shape components using additive manufacturing and HIP technologies, ensuring precision, material integrity, and reduced times for critical applications. It serves in industries of Aerospace, Defense, Energy, Oil & Gas, and Others. The group leverages cutting-edge gas atomization and hot isostatic pressing (HIP) technologies to create high-performance components that reduce porosity and improve material integrity. Its focus is on reshoring critical materials production and defense manufacturing, offering high-value refractory, specialty, and titanium alloyed powders.